Highlights and Quick Summary
- EBT margin for the quarter ending September 30, 2022 was -54.07% (a -38.91% decrease compared to previous quarter)
- Year-over-year quarterly EBT margin increased by 64.25%
- Annual EBT margin for 2021 was -115.68% (a -88.73% decrease from previous year)
- Annual EBT margin for 2020 was -1026.35% (a 360.27% increase from previous year)
- Annual EBT margin for 2019 was -222.99% (a -54.52% decrease from previous year)
- Twelve month EBT margin ending September 30, 2022 was -79.03% (a -21.98% decrease compared to previous quarter)
- Twelve month trailing EBT margin decreased by -31.68% year-over-year
Trailing EBT margin for the last four month:
30 Sep '22 | 30 Jun '22 | 31 Mar '22 | 31 Dec '21 |
---|---|---|---|
-79.03% | -101.3% | -101.81% | -115.68% |
Visit stockrow.com/BCRX
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical EBT margin of BioCryst Pharmaceuticals, Inc.
Most recent EBT marginof BCRX including historical data for past 10 years.Interactive Chart of EBT margin of BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. EBT margin for the past 10 Years (both Annual and Quarterly)
Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
---|---|---|---|---|---|
2022 | – | -54.07% | -88.51% | -148.06% | – |
2021 | -32.92% | -143.44% | -86.47% | -337.29% | -115.68% |
2020 | -1506.3% | -755.74% | -1344.72% | -779.58% | -1026.35% |
2019 | -6.6% | -2117.86% | -2598.69% | -527.5% | -222.99% |
2018 | -1005.2% | -2035.56% | -147.64% | -648.31% | -490.25% |
2017 | -502.39% | -172.76% | -544.89% | -150.67% | -261.18% |
2016 | -50.13% | -148.5% | -340.11% | -473.69% | -209.25% |
2015 | -394.07% | -133.08% | 18.97% | -222.15% | -89.15% |
2014 | -214.32% | -269.64% | -999.25% | -293.15% | -332.08% |
2013 | -51.38% | -334.91% | -1482.58% | -126.79% | -173.72% |
2012 | -269.52% | -168.37% | -291.59% | -49.52% | -148.64% |
Business Profile of BioCryst Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology